About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research group is focused on finding new molecular therapeutic targets and biomarkers based on knowledge of the biology of paediatric tumours, leukemias and hematologic diseases. The experience of the group in recent years has permitted the identification of new molecular targets that are very close to the clinical phase. In this stage, we have consolidated collaborations with the biotechnological industry in order to develop small molecules able to inhibit pro-oncogenic processes such as invasion or proliferation, with the aim of providing patients with innovative and more specific biological evidence-based therapies.
Another line of research is based on the study of liquid biopsy to develop a system based on NGS to monitor the probability of relapses.
Furthermore, we have implemented a personalized medicine program to guide the management of patients based on the molecular alterations of their tumours
PMID: 33205902 Journal: PEDIATRIC BLOOD & CANCER Year: 2021 Reference: Pediatr Blood Cancer. 2021 Mar;68(3):e28794. doi: 10.1002/pbc.28794. Epub 2020 Nov 18. Impact factor: 3.167 Publication type: Paper in international publication Authors: Irwin, Meredith S, Berthold, Frank, Hogarty, Michael, Kamijo, Takehiko, Morgenstern, Daniel, Pasqualini, Claudia, Ash, Shifra, Potschger, Ulrike, Ladenstein, Ruth, Valteau-Couanet, Dominique et al. DOI: 10.1002/pbc.28794
PMID: 33245207 Journal: PEDIATRIC BLOOD & CANCER Year: 2021 Reference: Pediatr Blood Cancer. 2021 Mar;68(3):e28832. doi: 10.1002/pbc.28832. Epub 2020 Nov 27. Impact factor: 3.167 Publication type: Paper in international publication Authors: Hawkins, Douglas S, Gallego, Soledad, Chi, Yueh-Yun, De Salvo, Gian Luca, Li, Minjie, Merks, Johannes H M, Rodeberg, David A, van Scheltinga, Sheila Terwisscha, Mascarenhas, Leo, Orbach, Daniel et al. DOI: 10.1002/pbc.28832
PMID: 33332189 Journal: JOURNAL OF CLINICAL ONCOLOGY Year: 2021 Reference: J Clin Oncol. 2021 Feb 1;39(4):295-307. doi: 10.1200/JCO.20.02529. Epub 2020 Dec 17. Impact factor: 44.544 Publication type: Paper in international publication Authors: Ariffin, Hany, Peters, Christina, Dalle, Jean-Hugues, Locatelli, Franco, Poetschger, Ulrike, Sedlacek, Petr, Buechner, Jochen, Shaw, Peter J, Staciuk, Raquel, Ifversen, Marianne et al. DOI: 10.1200/JCO.20.02529
PMID: 33084101 Journal: EUROPEAN JOURNAL OF HAEMATOLOGY Year: 2021 Reference: Eur J Haematol. 2021 Feb;106(2):196-204. doi: 10.1111/ejh.13536. Epub 2020 Nov 17. Impact factor: 2.997 Publication type: Paper in international publication Authors: Benito, Ana, Couselo, Jose Miguel, Fuster, Jose Luis, Diaz-Almiron, Mariana, Bueno, David, Mozo, Yasmina, Gomez Lopez, Alicia, Vicario, Jose Luis, Balas, Antonio, Sisinni, Luisa et al. DOI: 10.1111/ejh.13536
PMID: 31738823 Journal: BLOOD Year: 2020 Reference: Blood. 2020 Jan 23;135(4):274-286. doi: 10.1182/blood.2019002699. Impact factor: 17.543 Publication type: Paper in international publication Authors: Azorin, Daniel, Ramis-Zaldivar, Joan Enric, Gonzalez-Farre, Blanca, Balague, Olga, Celis, Veronica, Nadeu, Ferran, Salmeron-Villalobos, Julia, Andres, Mara, Martin-Guerrero, Idoia, Garrido-Pontnou, Marta et al. DOI: 10.1182/blood.2019002699
PMID: 31939050 Journal: CANCER AND METASTASIS REVIEWS Year: 2020 Reference: Cancer Metastasis Rev. 2020 Mar;39(1):149-160. doi: 10.1007/s10555-020-09856-z. Impact factor: 6.4 Publication type: Review in international publication Authors: de Rojas, Teresa, Neven, Anouk, Towbin, Alexander J, Carceller, Fernando, Bautista, Francisco, Riedl, David, Sodergren, Samantha, Darlington, Anne-Sophie, Fernandez-Teijeiro, Ana, Moreno, Lucas et al. DOI: 10.1007/s10555-020-09856-z
PMID: 31908304 Journal: LANCET ONCOLOGY Year: 2020 Reference: Lancet Oncol. 2020 Jan;21(1):e3. doi: 10.1016/S1470-2045(19)30812-5. Impact factor: 33.752 Publication type: Letter or abstract Authors: Bisogno, Gianni, Ferrari, Andrea, Melcon, Soledad Gallego, De Salvo, Gian Luca, Bergeron, Christophe, Jenney, Meriel et al. DOI: 10.1016/S1470-2045(19)30812-5
PMID: 31625177 Journal: AMERICAN JOURNAL OF HEMATOLOGY Year: 2020 Reference: Am J Hematol. 2020 Jan;95(1):28-37. doi: 10.1002/ajh.25661. Epub 2019 Nov 5. Impact factor: 6.973 Publication type: Paper in international publication Authors: Diaz, Miguel Angel, de Heredia, Cristina Diaz, Perez-Martinez, Antonio, Ferreras, Cristina, Pascual, Antonia, Gonzalez-Vicent, Marta, Alonso, Laura, Badell, Isabel, Navarro, Jose Maria Fernandez, Regueiro, Alexandra et al. DOI: 10.1002/ajh.25661
The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.
A study jointly led by the Hospital Clínic of Barcelona and the Vall d'Hebron Research Institute (VHIR) confirms the effectiveness of neonatal screening in reducing morbidity among children with sickle cell disease (SCD).
Active participation by patients and families in studies helps identify more effective therapies that improve quality of life and survival.
